March 27, 2014

Josh Hardy, first-grader taking Chimerix’s brincidofovir, leaves ICU

Josh Hardy, the first-grader taking Chimerix’s brincidofovir, leaves ICU. His mother said the boy’s medical condition has dramatically improved.

A critically ill first-grader taking an experimental medication made by Durham drug developer Chimerix has been moved out of intensive care and is improving dramatically, his mother said.

Josh Hardy, 7, became the first patient to take Chimerix’s antiviral, brincidofovir, as part of a small trial hastily arranged two weeks ago by Chimerix after the boy’s family mounted a social media campaign to obtain the medication.

Since Josh’s first infusion, the potentially lethal adenovirus has almost disappeared, his mother posted on Facebook on Tuesday. “Pretty much gone!,” Aimee Hardy wrote. “We are still waiting for his kidney function to return but we are definitely on the right path. Josh has made tremendous strides in the last week.”

Josh, a four-time cancer survivor, has been hospitalized at St. Jude Children’s Research Hospital in Tennessee since late December.

Chimerix and St. Jude have said they would not provide updates on Josh’s condition, making Aimee Hardy’s Facebook page an unofficial and unconfirmed source of information on bricidofovir’s effectiveness at wiping out a potent virus without toxic side effects.

Chimerix initially rebuffed the family’s pleas for help, resulting in death threats and an armed escort for the 54-employee company’s CEO, Kenneth Moch.

Chimerix stock closed at $24.06 on Thursday, down 10 cents a share.

Related content



Editor's Choice Videos